Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Breast cancer in 2012

New drugs, new knowledge, new targets

Nature Reviews Clinical Oncology volume 10, pages 75–76 (2013)Cite this article

Subjects

In 2012, we increased our knowledge of the molecular portrait of breast cancer. The BOLERO-2 and CLEOPATRA trials led to the approval of everolimus and pertuzumab; and the EMILIA trial will likely result in the approval of T-DM1. Some of these findings represent a paradigm shift in the way we think about the biology and management of breast cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).

    Article  CAS  Google Scholar 

  2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).

  3. Baselga, J. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138–1144 (2010).

    Article  CAS  Google Scholar 

  4. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).

    Article  CAS  Google Scholar 

  5. Krop, I. E. et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30, 3234–3241 (2012).

    Article  CAS  Google Scholar 

  6. Burris, H. A. 3rd et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398–405 (2011).

    Article  CAS  Google Scholar 

  7. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).

    Article  CAS  Google Scholar 

  8. Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452–4461 (2011).

    Article  CAS  Google Scholar 

  9. Bachelot, T. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30, 2718–2724 (2012).

    Article  CAS  Google Scholar 

  10. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by National Cancer Institute 1K23CA121994 (A. M. Gonzalez-Angulo), ASCO Career Development Award (A. M. Gonzalez-Angulo), Komen for the Cure Catalystic Award KG090341 (A. M. Gonzalez-Angulo), and National Cancer Institute through The University of Texas MD Anderson's Cancer Center Support Grant (P30 CA016672).

Author information

Authors and Affiliations

  1. Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Mariana Chavez-MacGregor & Ana Maria Gonzalez-Angulo

Authors
  1. Mariana Chavez-MacGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Maria Gonzalez-Angulo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Maria Gonzalez-Angulo.

Ethics declarations

Competing interests

M. Chavez-MacGregor receives research funding from Novartis Oncology. A. M. Gonzalez-Angulo is a consultant and receives research funding from Genentech and Novartis Oncology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chavez-MacGregor, M., Gonzalez-Angulo, A. New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10, 75–76 (2013). https://doi.org/10.1038/nrclinonc.2012.236

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.236

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer